Wall Street Reassessment: Analyst Opinion Evolution on CC. UBS, Morgan Stanley, and J.P. Morgan cut Chemours price targets by as much as 37.9% after a 2026 guidance cut that the lawsuit alleges followed months of overstated Opteon aftermarket demand. NEW YORK, Oct. 14, 2026 /PRNewswire/...